Table 2. Univariable and multivariable... | American Society of Hematology

Table 2.

Univariable and multivariable analysis for survival in patients with stage IIIb amyloidosis

Univariable analysis (249 patients)
Variables	Hazard ratio	95% CI	P
Sex, male	1.22	0.96-1.67	0.158
NYHA class I	0.57	0.37-0.89	0.014
Troponin I > 0.500 ng/mL	1.50	1.10-2.50	0.010
NT-proBNP(ln), ng/L	1.53	0.81-2.87	0.186
eGFR < 30 mL/min × 1.73 m²	0.71	0.52-0.96	0.028
LC isotype κ vs λ	1.18	0.84-1.66	0.326
dFLC > 50 mg/L	0.53	0.26-1.09	0.083
dFLC > 180 mg/L	1.17	0.87-1.56	0.296
dFLC > 500 mg/L	1.94	1.43-2.63	<0.001
BMPC > 20%	1.03	0.65-1.63	0.888
Bortezomib-based treatment, yes	0.85	0.65-1.12	0.254
Treatment with CyBorD, yes	0.81	0.59-1.11	0.192
Treatment with BMDex, yes	1.22	0.85-1.74	0.274
Treatment with MDex, yes	1.02	0.77-1.35	0.906

Univariable analysis (249 patients)
Variables	Hazard ratio	95% CI	P
Sex, male	1.22	0.96-1.67	0.158
NYHA class I	0.57	0.37-0.89	0.014
Troponin I > 0.500 ng/mL	1.50	1.10-2.50	0.010
NT-proBNP(ln), ng/L	1.53	0.81-2.87	0.186
eGFR < 30 mL/min × 1.73 m²	0.71	0.52-0.96	0.028
LC isotype κ vs λ	1.18	0.84-1.66	0.326
dFLC > 50 mg/L	0.53	0.26-1.09	0.083
dFLC > 180 mg/L	1.17	0.87-1.56	0.296
dFLC > 500 mg/L	1.94	1.43-2.63	<0.001
BMPC > 20%	1.03	0.65-1.63	0.888
Bortezomib-based treatment, yes	0.85	0.65-1.12	0.254
Treatment with CyBorD, yes	0.81	0.59-1.11	0.192
Treatment with BMDex, yes	1.22	0.85-1.74	0.274
Treatment with MDex, yes	1.02	0.77-1.35	0.906

Multivariable analysis (173 patients with eGFR > 30 mL/min × 1.73 m²)
NYHA class I	0.80	0.48-1.33	0.392
Troponin I > 0.500 ng/mL	1.22	0.81-1.83	0.340
dFLC > 500 mg/L	1.83	1.28-2.62	0.001

Multivariable analysis (173 patients with eGFR > 30 mL/min × 1.73 m²)
NYHA class I	0.80	0.48-1.33	0.392
Troponin I > 0.500 ng/mL	1.22	0.81-1.83	0.340
dFLC > 500 mg/L	1.83	1.28-2.62	0.001

BMDex, bortezomib, melphalan, and dexamethasone; CI, confidence interval; CyBorD, cyclophosphamide, bortezomib, and dexamethasone; LC, light chains.